Metastasis-directed stereotactic radiotherapy for oligoprogressive castration-resistant prostate cancer: a multicenter study: World Journal of Urology

L. Triggiani, R. Mazzola, S.M. Magrini, G. Ingrosso, P. Borghetti, F. Trippa, A. Lancia, B. Detti, G. Francolini, F. Matrone, R. Bortolus, G. Fanetti, E. Maranzano, F. Pasqualetti, F. Paiar, M.L. Bonù, A. Magli, A. Bruni, E. Mazzeo, C. FranzeseM. Scorsetti, F. Alongi, B.A. Jereczek-Fossa, P. Ost, M. Buglione

Research output: Contribution to journalArticle

Abstract

Purpose: Herein, we report the clinical outcomes of a multicenter study evaluating the role of SBRT in a cohort of patients affected by oligoprogressive castration-resistant prostate cancer (CRPC). Materials and methods: This is a retrospective multicenter observational study including eleven centers. Inclusion criteria of the current study were: (a) Karnofsky performance status > 80, (b) histologically proven diagnosis of PC, (c) 1–5 oligoprogressive metastases, defined as progressive disease at bone or nodes levels (detected by means of choline PET/CT or CT plus bone scan) during ADT, (d) serum testosterone level under 50 ng/ml during ADT, (e) controlled primary tumor, (f) patients treated with SBRT with a dose of at least 5 Gy per fraction to a biologically effective dose (BED) of at least 80 Gy using an alpha-to-beta ratio of 3 Gy, (g) at least 6 months of follow-up post-SBRT. Results: Eighty-six patients for a total of 117 lesions were treated with SBRT. The median follow-up was 30.7 months (range 4–91 months). The median new metastasis-free survival after SBRT was 12.3 months (95% CI 5.5–19.1 months). One- and two-year distant progression-free survival was 52.3% and 33.7%, respectively. Twenty-six out of 86 patients underwent a second course of SBRT due to further oligoprogressive disease: This resulted in a median systemic treatment-free survival of 21.8 months (95% CI 17.8–25.8 months). One-year systemic treatment-free survival was 72.1%. Conclusion: SBRT appears to be a promising approach in oligoprogressive castration-resistant prostate cancer. Further investigations are warranted. © 2019, Springer-Verlag GmbH Germany, part of Springer Nature.
Original languageEnglish
Pages (from-to)2631-2637
Number of pages7
JournalWorld J. Urol.
Volume37
Issue number12
DOIs
Publication statusPublished - 2019

Keywords

  • CRPC
  • Metastasis-directed therapy
  • Prostate cancer
  • Radiotherapy
  • SBRT

Fingerprint Dive into the research topics of 'Metastasis-directed stereotactic radiotherapy for oligoprogressive castration-resistant prostate cancer: a multicenter study: World Journal of Urology'. Together they form a unique fingerprint.

  • Cite this

    Triggiani, L., Mazzola, R., Magrini, S. M., Ingrosso, G., Borghetti, P., Trippa, F., Lancia, A., Detti, B., Francolini, G., Matrone, F., Bortolus, R., Fanetti, G., Maranzano, E., Pasqualetti, F., Paiar, F., Bonù, M. L., Magli, A., Bruni, A., Mazzeo, E., ... Buglione, M. (2019). Metastasis-directed stereotactic radiotherapy for oligoprogressive castration-resistant prostate cancer: a multicenter study: World Journal of Urology. World J. Urol., 37(12), 2631-2637. https://doi.org/10.1007/s00345-019-02717-7